Trastuzumab Deruxtecan (T-Dxd) Vs Physician’s Choice of Chemotherapy (TPC) in Patients (pts) with Hormone Receptor-Positive (HR+), Human Epidermal Growth Factor Receptor 2 (Her2)-Low or HER2-ultralow Metastatic Breast Cancer (mbc) with Prior Endocrine Therapy (ET): Primary Results from DESTINY-Breast06 (DB-06).